Aptamer therapeutics useful in the treatment of complement-related disorders

1. A method of treating a C5 complement protein, C5a and/or C5b-9-mediated disorder, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound having the structure set forth below or a salt thereof:

where,

 indicates a linker

Aptamer=fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfUfUAfCfCfUmGfCmG-3T (SEQ ID NO:4),

wherein fC and fU=2′-fluoro nucleotides, and mG and rnA=2′-OMe nucleotides and all other nucleotides are 2′-OH and 3T indicates an inverted deoxy thymidine.

2. The method of claim 1 , wherein the linker is an alkyl linker.

3. The method of claim 2 , wherein the alkyl linker comprises 2 to 18 consecutive CH 2 groups.

4. The method of claim 1 , wherein the compound has the structure set forth below or a salt thereof:

where Aptamer=fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfUfUAfCfCfUmGf CmG-3T (SEQ ID NO 4),

wherein fC and fU=2′-fluoro nucleotides, and mG and rnA=2′-OMe nucleotides and all other nucleotides are 2′-OH and 3T indicates an inverted deoxy thymidine.

5. The method of claim 1 or 4 , wherein the disorder to be treated is myocardial injury relating to CABG surgery, myocardial injury relating to balloon angioplasty or myocardial injury relating to restenosis.

6. The method of claim 1 or 4 , wherein the disorder to be treated is C5, C5a and/or C5b-9 complement protein mediated complications relating to CABG surgery.

7. The method of claim 1 or 4 , wherein the disorder to be treated is C5 mediated complement complications relating to percutaneous coronary intervention.

8. The method of claim 1 or 4 , wherein the disorder to be treated is paroxysomal nocturnal hemoglobinuria.

9. The method of claim 1 or 4 , wherein the disorder to be treated is acute transplant rejection, hyperacute transplant rejection, subacute transplant rejection or chronic transplant rejection.

10. The method of claim 1 or 4 , wherein the disorder to be treated is complement mediated ocular tissue damage.